PRECIGEN, INC. Long-Term Debt, Maturity, after Year Five
PRECIGEN, INC. (PGEN) had Long-Term Debt, Maturity, after Year Five of $0 as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2026-03-25
- 2025-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
- 2025-09-30: Long-Term Debt, Maturity, after Year Five $0.00.
- 2022-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
- 2022-03-31: Long-Term Debt, Maturity, after Year Five $861.00K.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-06 |
| 2022-03-31 | $861.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.32M 10-K · filed 2022-03-01 |
| 2021-09-30 | $1.35M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $1.38M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.42M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.85M 10-K · filed 2021-03-01 |
| 2020-09-30 | $1.89M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $1.92M 10-Q · filed 2020-08-10 |
| 2019-12-31 | $2.37M 10-K · filed 2020-03-02 |
| 2018-12-31 | $2.94M 10-K · filed 2019-03-01 |
| 2017-12-31 | $3.44M 10-K · filed 2018-03-01 |
| 2016-12-31 | $3.79M 10-K · filed 2017-03-01 |
| 2015-12-31 | $4.23M 10-K · filed 2016-02-29 |
| 2014-12-31 | $4.82M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |